Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251 |
Resumo: | Introduction: High values of lipoprotein(a), related to atherosclerosis progression, are often considered a marker of thrombosis. We assessed the lipoprotein(a) profile in a group of patients with high vascular risk and no cardiovascular events, established its correlation with other cardiovascular risk factors and inferred the results for patients with metabolic disorders and, at least, two risk factors.Material and Methods: This longitudinal observational study included 516 patients, who had at least two cardiovascular risk factors and regularly attended, for at least two years, the outpatient consultations at a clinic of metabolism and vascular risk for primary prevention. Sociodemographic, clinical and anthropometric parameters were obtained at the baseline visit. Hepatic morphology was assessed in 509 patients (98.6%) by ultrasonography. The 10-year vascular risk was estimated using Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation tables.Results: Significant correlations were found between lipoprotein(a) levels and the addressed vascular risk factors, as well as between lipoprotein(a), and Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation charts. Lipoprotein(a) values were also considerably higher in patients with steatosis.Discussion: Increased lipoprotein(a) values were directly associated with all markers of cardiovascular risk and with non-alcoholic hepatic steatosis.Conclusion: Due to its high availability and low cost, lipoprotein(a) should become part of the routine evaluation of patients at vascular risk. |
id |
RCAP_2cb624007eaf5c54148b3621e60aca6a |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/10251 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese PopulationLipoproteína(a) na Avaliação do Risco Cardiovascular na População PortuguesaAtherosclerosisCardiovascular DiseasesLipoprotein(a)PortugalPrimary PreventionAteroscleroseDoenças CardiovascularesLipoproteína(a)PortugalPrevenção PrimáriaIntroduction: High values of lipoprotein(a), related to atherosclerosis progression, are often considered a marker of thrombosis. We assessed the lipoprotein(a) profile in a group of patients with high vascular risk and no cardiovascular events, established its correlation with other cardiovascular risk factors and inferred the results for patients with metabolic disorders and, at least, two risk factors.Material and Methods: This longitudinal observational study included 516 patients, who had at least two cardiovascular risk factors and regularly attended, for at least two years, the outpatient consultations at a clinic of metabolism and vascular risk for primary prevention. Sociodemographic, clinical and anthropometric parameters were obtained at the baseline visit. Hepatic morphology was assessed in 509 patients (98.6%) by ultrasonography. The 10-year vascular risk was estimated using Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation tables.Results: Significant correlations were found between lipoprotein(a) levels and the addressed vascular risk factors, as well as between lipoprotein(a), and Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation charts. Lipoprotein(a) values were also considerably higher in patients with steatosis.Discussion: Increased lipoprotein(a) values were directly associated with all markers of cardiovascular risk and with non-alcoholic hepatic steatosis.Conclusion: Due to its high availability and low cost, lipoprotein(a) should become part of the routine evaluation of patients at vascular risk.Introdução: Valores elevados de lipoproteína(a), relacionados com a progressão da aterosclerose, são frequentemente considerados marcadores de trombose. O perfil de lipoproteína(a) foi avaliado num grupo de doentes sem eventos cardiovasculares mas com elevado risco vascular, estabelecendo-se a correlação com outros fatores de risco cardiovascular e inferindo-se os resultados para doentes com alterações metabólicas e, pelo menos, dois fatores de risco vascular.Material e Métodos: Este estudo observacional longitudinal incluiu 516 doentes com, pelo menos, dois fatores de risco cardiovascular e que frequentavam, regularmente e há pelo menos dois anos, a consulta ambulatória de metabolismo e risco vascular para prevenção primária. Os parâmetros sociodemográficos, clínicos e antropométricos foram recolhidos na primeira visita. A morfologia hepática foi avaliada por ultrassonografia em 509 doentes (98,6%). O risco vascular a 10 anos foi estimado através de tabelas de cálculo de risco de Framingham, doença cardiovascular e risco coronário sistemático.Resultados: Foram encontradas correlações significativas entre os níveis de lipoproteína(a) e os fatores de risco vasculares analisados, assim como entre lipoproteína(a) e as escalas de risco de Framingham, doença cardiovascular e risco coronário sistemático. Os valores de lipoproteína(a) apresentaram-se mais elevados em doentes com esteatose.Discussão: Os valores elevados de lipoproteína(a) estão diretamente associados com todos os marcadores de risco cardiovascular e com esteatose hepática não alcoólica.Conclusão: Como tal, considerando a sua elevada acessibilidade e custo reduzido, o marcador lipoproteína(a) deverá ser integrado na avaliação de rotina de doentes com risco vascular.Ordem dos Médicos2019-03-29info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfapplication/pdfapplication/mswordapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251oai:ojs.www.actamedicaportuguesa.com:article/10251Acta Médica Portuguesa; Vol. 32 No. 3 (2019): March; 202-207Acta Médica Portuguesa; Vol. 32 N.º 3 (2019): Março; 202-2071646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/5654https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/9909https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/10744https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/10879Direitos de Autor (c) 2019 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessMeireles-Brandão, Joaquim A.Meireles-Brandão, Lúcia R.Coelho, RuiRocha-Gonçalves, Francisco R.2022-12-20T11:05:55Zoai:ojs.www.actamedicaportuguesa.com:article/10251Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:51.087428Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population Lipoproteína(a) na Avaliação do Risco Cardiovascular na População Portuguesa |
title |
Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population |
spellingShingle |
Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population Meireles-Brandão, Joaquim A. Atherosclerosis Cardiovascular Diseases Lipoprotein(a) Portugal Primary Prevention Aterosclerose Doenças Cardiovasculares Lipoproteína(a) Portugal Prevenção Primária |
title_short |
Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population |
title_full |
Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population |
title_fullStr |
Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population |
title_full_unstemmed |
Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population |
title_sort |
Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population |
author |
Meireles-Brandão, Joaquim A. |
author_facet |
Meireles-Brandão, Joaquim A. Meireles-Brandão, Lúcia R. Coelho, Rui Rocha-Gonçalves, Francisco R. |
author_role |
author |
author2 |
Meireles-Brandão, Lúcia R. Coelho, Rui Rocha-Gonçalves, Francisco R. |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Meireles-Brandão, Joaquim A. Meireles-Brandão, Lúcia R. Coelho, Rui Rocha-Gonçalves, Francisco R. |
dc.subject.por.fl_str_mv |
Atherosclerosis Cardiovascular Diseases Lipoprotein(a) Portugal Primary Prevention Aterosclerose Doenças Cardiovasculares Lipoproteína(a) Portugal Prevenção Primária |
topic |
Atherosclerosis Cardiovascular Diseases Lipoprotein(a) Portugal Primary Prevention Aterosclerose Doenças Cardiovasculares Lipoproteína(a) Portugal Prevenção Primária |
description |
Introduction: High values of lipoprotein(a), related to atherosclerosis progression, are often considered a marker of thrombosis. We assessed the lipoprotein(a) profile in a group of patients with high vascular risk and no cardiovascular events, established its correlation with other cardiovascular risk factors and inferred the results for patients with metabolic disorders and, at least, two risk factors.Material and Methods: This longitudinal observational study included 516 patients, who had at least two cardiovascular risk factors and regularly attended, for at least two years, the outpatient consultations at a clinic of metabolism and vascular risk for primary prevention. Sociodemographic, clinical and anthropometric parameters were obtained at the baseline visit. Hepatic morphology was assessed in 509 patients (98.6%) by ultrasonography. The 10-year vascular risk was estimated using Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation tables.Results: Significant correlations were found between lipoprotein(a) levels and the addressed vascular risk factors, as well as between lipoprotein(a), and Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation charts. Lipoprotein(a) values were also considerably higher in patients with steatosis.Discussion: Increased lipoprotein(a) values were directly associated with all markers of cardiovascular risk and with non-alcoholic hepatic steatosis.Conclusion: Due to its high availability and low cost, lipoprotein(a) should become part of the routine evaluation of patients at vascular risk. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-03-29 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251 oai:ojs.www.actamedicaportuguesa.com:article/10251 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/10251 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/5654 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/9909 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/10744 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10251/10879 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2019 Acta Médica Portuguesa info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2019 Acta Médica Portuguesa |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/msword application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 32 No. 3 (2019): March; 202-207 Acta Médica Portuguesa; Vol. 32 N.º 3 (2019): Março; 202-207 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130648358682624 |